paricalcitol: Clinical Trials

30 trials of paricalcitol, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

23 completed, 5 terminated, 2 unknown. 30 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 430Completed 23, Terminated 5, Unknown 2

Follow paricalcitol: new trials by email Literature Review of paricalcitol trials Research Report on paricalcitol

Trials (filtered) newest first · largest first

All 30 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency
Calcifediol Oral Capsule, Calcifediol Oral Product, Cholecalciferol - Secondary Hyperparathyroidism Due to Renal Causes, Vitamin D Insufficiency
Phase 4CompletedOPKO Health, Inc.692018-06-082022-12-09
Paricalcitol Improves Anemia of Inflammation
Paricalcitol, Epoetin beta, Placebo - Anemia
Phase 4TerminatedHospital Son Espases192014-12-012024-12-09
Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation.
Paricalcitol, Calcifediol - Secondary Hyperparathyroidism Due to Renal Causes
Phase 4CompletedFundación Senefro1482014-01-012018-11-19
Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol
Calcitriol, Paricalcitol - Kidney Failure, Secondary Hyperparathyroidism
Phase 4TerminatedWinthrop University Hospital162012-11-012023-11-07
Effect of Paricalcitol Over Vessel Wall
Paricalcitol - Nephropathy
Phase 4TerminatedEffice Servicios Para la Investigacion S.L.502012-07-012015-02-26
A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients
Paricalcitol, Darbepoetin alfa - Moderate to Severe Secondary Hyperparathyroidism, Stage 5 Chronic Kidney Diseases
Phase 4CompletedAbbVie (prior sponsor, Abbott)652012-05-102021-07-30
Value Antiproteinuric Effects From Vitamin D Derivatives in Patient With Chronic Kidney Illness and the Lack of Vitamin D
Hidroferol®, Paricalcitol: Zemplar®, Habitual medication - Kidney Failure, Chronic, Disorder of Vitamin D
Phase 4UnknownHospital Universitario de Canarias1742012-01-012012-05-21
Intravenous Paricalcitol in Chronic Hemodialysis Patients
Intravenous Paricalcitol - Endstage Renal Disease, Secondary Hyperparathyroidism
Phase 4UnknownThe University of Hong Kong302011-09-012017-01-18
Paricalcitol Effect on Anemia in CKD
Paricalcitol, Calcitriol - Anemia, Chronic Kidney Disease
Phase 4CompletedFederico II University602010-10-012014-07-30
The Effect of Paricalcitol on Creatinine Filtration, Secretion and Glomerular Filtration Rate
Paricalcitol - Chronic Kidney Disease
Phase 4CompletedIndiana University162010-08-012013-05-21
Effect of a Vitamin D Analogue vs Placebo on p-NT-proBNP in Patients With Type 1 DM and Diabetic Nephropathy
Paricalcitol - Cardiovascular Disease, Diabetic Nephropathy
Phase 4CompletedPeter Rossing482010-04-012012-04-13
Trial to Optimize Mineral Outcomes in Dialysis Patients
Cinacalcet, active vitamin D analogue - Secondary Hyperparathyroidism, Chronic Kidney Disease
Phase 4CompletedUniversity of Colorado, Denver922010-03-012017-01-02
Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D
Paricalcitol, Cinacalcet - Chronic Kidney Disease, Secondary Hyperparathyroidism
Phase 4CompletedAbbott2722009-11-012012-06-20
Paricalcitol Versus Calcitriol for the Management of Renocardiac Syndrome in Renal Transplant Patients
Paricalcitol, Calcitriol, Cholecalciferol - Cardiorenal Syndrome, Chronic Allograft Nephropathy
Phase 4CompletedUral State Medical University1092009-10-012015-06-09
Vitamin D Deficiency in Chronic Kidney Disease (CKD) Patients
Paricalcitol, Ergocalciferol - Secondary Hyperparathyroidism, Chronic Kidney Disease
Phase 4CompletedSalem Veterans Affairs Medical Center802009-07-012011-03-24
Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose
Zemplar (paricalcitol) - Secondary Hyperparathyroidism, Renal Insufficiency, Chronic
Phase 4CompletedAbbott1002009-05-012011-10-31
Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT)
Paricalcitol, Calcitriol - Secondary Hyperparathyroidism, Chronic Kidney Disease
Phase 4CompletedWashington University School of Medicine1102009-02-012014-08-07
Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis Subjects
Calcitriol, Paricalcitol - Secondary Hyperparathyroidism, Dialysis
Phase 4TerminatedAbbott132009-01-012012-01-20
Vitamin D and Coronary Calcification Study
Calcitriol (Rocaltrol®), Paricalcitol - Chronic Kidney Disease, Vitamin D Deficiency
Phase 4CompletedJoslin Diabetes Center442008-09-012017-12-08
Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis
Paricalcitol injection, Paricalcitol capsules - Secondary Hyperparathyroidism, Dialysis
Phase 4CompletedAbbott1472007-09-012011-10-25

Showing 20 of 30. Sign in to see all of them.

Conditions studied

Hyperparathyroidism, Secondary (18)  ·  Renal Insufficiency, Chronic (12)  ·  Kidney Failure, Chronic (6)  ·  Hypercalcemia (4)  ·  Hyperparathyroidism (3)  ·  Anemia (2)  ·  Hyperphosphatemia (2)  ·  Kidney Diseases (2)  ·  Renal Insufficiency (2)  ·  Vitamin D Deficiency (2)  ·  Cardio-Renal Syndrome (1)  ·  Cardiovascular Diseases (1)  ·  Diabetic Nephropathies (1)  ·  Inflammation (1)

Sponsors

Abbott (9)  ·  Genzyme, a Sanofi Company (2)  ·  AbbVie (prior sponsor, Abbott) (1)  ·  Amgen (1)  ·  Effice Servicios Para la Investigacion S.L. (1)  ·  Federico II University (1)  ·  Fresenius Medical Care North America (1)  ·  Fundación Senefro (1)  ·  Hospital Son Espases (1)  ·  Hospital Universitario de Canarias (1)  ·  Indiana University (1)  ·  Joslin Diabetes Center (1)  ·  OPKO Health, Inc. (1)  ·  Papageorgiou General Hospital (1)  ·  Peter Rossing (1)

Countries

United States (15)  ·  Spain (4)  ·  Denmark (2)  ·  Greece (2)  ·  Italy (2)  ·  Netherlands (2)  ·  Russia (2)  ·  Brazil (1)  ·  Czechia (1)  ·  Germany (1)  ·  Hong Kong (1)  ·  Mexico (1)  ·  Peru (1)  ·  Portugal (1)  ·  Sweden (1)

Top investigators

Alexander Kharlamov, M.D. (1)  ·  Alexander Perrish, M.D. (1)  ·  Angela YM Wang, MD PhD (1)  ·  Csaba P. Kovesdy, M.D. (1)  ·  Daniel W Coyne, MD (1)  ·  David M Spiegel, MD (1)  ·  Efstathios Mitsopoulos, MD (1)  ·  Eleonora Riccio, MD (1)  ·  Jin Tian, M.D. (1)  ·  Josep M Cruzado, Dr (1)  ·  Laura Williams, M.D. (1)  ·  Lino Rodrigues, MD (1)

Results publications

PMID 21716260, PMID 22387567, PMID 22839442, PMID 24214232, PMID 24500308, PMID 24970869, PMID 25781618, PMID 32775985

NIH funding

2009 (2)